MSF Access

09/04/2026

Recent funding constraints for biomedical research in Africa have highlighted the urgent need to build a more sustainable and equitable research and development (R&D) ecosystem on the continent.

On 19 February 2026, MSF Access convened a panel of leading experts to discuss the broader implications of declining R&D funding across the African continent and the opportunities emerging within this changing global health landscape.

Read our report, which distils the key insights from that discussion👉

Issue brief on the shifting landscape of global health R&D funding, highlighting expert insights, key barriers, and opportunities to build more equitable research partnerships in Africa.

07/04/2026

Argentina has revoked key pharmaceutical patentability guidelines, a roll-back that could create and extend more monopolies, and, ultimately, delay or deny people’s access to affordable healthcare.

Argentina took a step backwards last month when it revoked key guidelines that defined what could – and could not – be patented in its pharmaceutical sector.

06/04/2026

Ebola: Rethinking Post-Exposure Prophylaxis

A new MSF analysis sheds light on how monoclonal antibodies can increase protection for people after exposure to Ebola.

What’s needed now is more research and improved access to this promising treatment for healthcare workers and community members.

Prophylaxie post-exposition contre le virus Ebola : arguments en faveur d'un élargissement du rôle des anticorps monoclonaux dans un contexte d'accès limité Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access Jul...

01/04/2026

01/04/2026

Before the diagnosis, Hareem and Ahmad were often unwell. They had poor appetite, abdominal pain, irritability, and were becoming weak. Their mother had taken them to a nearby clinic where they were given medicines without proper diagnosis, but their condition did not improve.

Under MSF's TACTiC initiative, the children were called to the MSF facility, where both Hareem and Ahmad were diagnosed with DR-TB. They are now receiving treatment at the clinic.

More about TACTiC 👉 https://www.msf.org/tactic-tuberculosis-children

30/03/2026

“The tools to diagnose and treat children with TB exist, even if imperfect, yet only half of the children who have TB are diagnosed or treated. For a truly global TB response, children must be prioritised now,” said Cathy Hewison, TB working group lead, MSF.

26/03/2026

“AMR in conflict or humanitarian settings is right there. It’s in front of us. We're already dealing with it.” Dr Kalyan Velivela, MSF health programme manager for South Sudan, Ethiopia, and Nigeria.

Addressing AMR in humanitarian settings means acting on our shared experiences.

The conclusions in our report, “Antimicrobial resistance in conflict-affected settings,” can help guide people-centered responses to AMR while recognising the resource limitations, operational constraints, and unpredictability of humanitarian settings.

https://msfaccess.org/antimicrobial-resistance-conflict-affected-settings-field-realities-operational-challenges-policy

24/03/2026

On , MSF urges governments and donors to put children at the heart of the global TB response. Sustained funding is needed to diagnose, treat, and prevent TB in children, who remain one of the most vulnerable groups. Children like Francisco, 10, who only received TB diagnosis after eight months of illness.

No child should suffer or die from a disease that is preventable and curable, and that starts with a timely diagnosis. There is a proven way to increase the diagnosis of TB in children under 10 years of age: World Health Organization (WHO) algorithms. Based on recent MSF research, the use of the WHO algorithms can nearly double the number of children who can be diagnosed with TB and initiated on lifesaving treatment.

Dr Moussa Mamane Oumarou Farouk, TB focal point for MSF in Niger highlighted: “Nearly half of the children under 5 with TB in the country have been diagnosed in the 5 districts where MSF supports the implementation of the algorithms, out of the 72 districts in the country.”

20/03/2026

Drawing on MSF’s frontline experience across emergencies, we’re calling on EU to progress towards a system that ensures fair and equitable benefit‑sharing in exchange for access to pathogens and genetic resources used in R&D, including clinical trials

EU must guarantee access to medical tools for communities sharing pathogens and data

06/03/2026

In 2011, we marched with more than 3,000 people in India to oppose harmful provisions that could have been included in EU–India free trade agreement and threatened access to affordable medicines. Fifteen years later, after two decades of sustained advocacy, those were excluded from the final deal.

The intellectual Property chapter of this trade deal largely preserves India’s public health safeguards and does not include any harmful provisions that go beyond the World Trade Organization’s TRIPS agreement, such as data exclusivity or patent term extensions.

“We welcome the positive outcomes of this agreement, which ensures that provisions expanding pharmaceutical monopolies beyond international trade rules are not included. As an international medical humanitarian organisation, MSF has seen firsthand how health safeguards in Indian laws have prevented unwarranted monopolies and kept lifesaving medicines within reach for people in low- and middle-income countries,” said Roshan Joseph, Legal and Policy Advisor, MSF Access. And he warned: “At the same time, we call on Government of India to ensure careful implementation of the enforcement and trade secret provisions which will be crucial to maintaining these hard-earned gains and ensuring they do not block the entry of affordable generics into the market. Medicines and medical tools should never be a luxury.”

“We hope the positive elements of the intellectual property in the EU-India trade agreement serve as a template for other countries, enabling them to resist pressure during trade negotiations and safeguard access to affordable medicines,” added Parthesarathy Rajendran, Executive Director, MSF South Asia.

Read our full reaction: https://msfaccess.org/dnp-and-msf-welcome-removal-harmful-ip-provisions-eu-india-fta-call-continued-vigilance

13/02/2026

For years, MSF's own experience of responding to infectious disease outbreaks, epidemics and pandemics has shown that patients and communities who contribute vital samples, data, and clinical participation to lifesaving innovations are too often left behind and denied access to the very products they help make possible. MSF has advocated for the WHO Pandemic Agreement to establish a multilateral system that ensures fair and equitable benefit-sharing in exchange for access to pathogens and genetic resources used in research and development (R&D), including clinical trials. Read MSF’s recent recommendations for a strong and effective WHO Pathogen Access and Benefit-Sharing (PABS) System capable of delivering reliable, equitable, and accountable access to vaccines, diagnostics, and treatments developed from shared samples and data.

MSF recommendations on WHO Pathogen Access and Benefit-Sharing (PABS) systems

06/02/2026

MSF representatives addressed critical issues in fragile settings at the World Health Organization (WHO) Executive Board this week, calling for urgent action on:

🔹Antimicrobial resistance: https://msfaccess.org/updated-global-action-plan-antimicrobial-resistance-eb15818
🔹Mental health: https://msfaccess.org/mental-health-implementation-related-resolutions-and-decisions-report-director-general-provisional
🔹Noncommunicable diseases: https://msfaccess.org/follow-political-declaration-high-level-meeting-general-assembly-noncommunicable-diseases
🔹Vaccines: https://msfaccess.org/immunisation-agenda-2030-eb1588

Read the statements: https://msfaccess.org/msf-statements-who-executive-board-158th-session

MSF Statement: EB158/6